2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Circulation

Volumn 135, Issue 25, 2017, Pages e1159-e1195

  Nishimura, Rick A ^a   Otto, Catherine M ^a   Bonow, Robert O ^a   Carabello, Blase A ^a   Erwin, John P ^a   Fleisher, Lee A ^a   Jneid, Hani ^a   Mack, Michael J ^a   McLeod, Christopher J ^a   O'Gara, Patrick T ^a   Rigolin, Vera H ^a   Sundt, Thoralf M ^a   Thompson, Annemarie ^a  

^a NONE

Author keywords

AHA Scientific Statements; anticoagulation therapy; aortic stenosis; cardiac surgery; heart valves; mitral regurgitation; prosthetic valves; transcatheter aortic valve replacement; tricuspid stenosis; valvular heart disease

Indexed keywords

ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; AORTIC STENOSIS; BACTERIAL ENDOCARDITIS; CHRONIC DISEASE; DISEASE SEVERITY; FOLLOW UP; HEALTH CARE QUALITY; HEART VALVE PROSTHESIS; HEART VALVE REGURGITATION; HEART VALVE STENOSIS; HUMAN; MEDICAL PRACTICE; MEDICAL SOCIETY; MITRAL VALVE REGURGITATION; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTHETIC VALVE THROMBOSIS; REVIEW; UNITED STATES; VALVULAR HEART DISEASE; FEMALE; MALE; PATHOLOGY; PATHOPHYSIOLOGY;

AMERICAN HEART ASSOCIATION; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 85015180713     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000503     Document Type: Review

References (286)

1. Committee on Standards for Developing Trustworthy Clinical Practice Guidelines, Institute of Medicine (U.S.) Clinical Practice Guidelines We Can Trust 2011 Washington, DC Press NA
2. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Institute of Medicine (U.S.) Finding What Works in Health Care: Standards for Systematic Reviews 2011 Washington, DC Press NA
3. Anderson JL, Heidenreich PA, Barnett PG, ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation 2014 129 2329 45
4. ACCF/AHA Task Force on Practice Guidelines Methodology Manual and Policies From the ACCF/AHA Task Force on Practice Guidelines. American College of Cardiology and American Heart Association2010. Available at: http://assets.cardiosource.com/Methodology-Manual-for-ACC-AHA-Writing-Committees.pdf. Accessed February 2017
5. Halperin JL, Levine GN, Al-Khatib SM, Birtcher K, Bozkurt B, Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016 133 1426 28
6. Jacobs AK, Kushner FG, Ettinger SM, ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013 127 268 310
7. Jacobs AK, Anderson JL, Halperin JL, The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 130 1208 17
8. Arnett DK, Goodman RA, Halperin JL, Anderson JL, Parekh AK, Zoghbi WA, AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. Circulation 2014 130 1662 7
9. Nishimura RA, Otto CM, Bonow RO, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 129 2440 92
10. Nishimura R, Otto CM, Bonow RO, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014 129 e521 643
11. Wilson W, Taubert KA, Gewitz M, Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007 116 1736 54
12. Habib G, Lancellotti P, Antunes MJ, 2015 ESC Guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Eur Heart J 2015 36 3075 128
13. Glenny AM, Oliver R, Roberts GJ, Hooper L, Worthington HV, Antibiotics for the prophylaxis of bacterial endocarditis in dentistry. Cochrane Database Syst Rev 2013 CD003813
14. (NICE) UNIfHaCE. Prophylaxis against infective endocarditis: antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. Available at: https://www.nice.org.uk/guidance/cg64. Accessed January 20, 2017
15. Mougeot FKB, Saunders SE, Brennan MT, Lockhart PB, Associations between bacteremia from oral sources and distant-site infections: tooth brushing versus single tooth extraction. Oral Surg Oral Med Oral Pathol Oral Radiol 2015 119 430 5
16. Desimone DC, Tleyjeh IM, Correa de Sa DD, Incidence of infective endocarditis caused by viridans group streptococci before and after publication of the 2007 American Heart Association's endocarditis prevention guidelines. Circulation 2012 126 60 4
17. Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH, Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis. Lancet 2015 385 1219 28
18. Duval X, Delahaye F, Alla F, Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys. J Am Coll Cardiol 2012 59 1968 76
19. Pasquali SK, He X, Mohamad Z, Trends in endocarditis hospitalizations at US children's hospitals: impact of the 2007 American Heart Association Antibiotic Prophylaxis Guidelines. Am Heart J 2012 163 894 9
20. Pant S, Patel NJ, Deshmukh A, Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. J Am Coll Cardiol 2015 65 2070 6
21. Thornhill MH, Dayer MJ, Forde JM, Impact of the NICE guideline recommending cessation of antibiotic prophylaxis for prevention of infective endocarditis: before and after study. BMJ 2011 342 d2392
22. Strom BL, Abrutyn E, Berlin JA, Risk factors for infective endocarditis: oral hygiene and nondental exposures. Circulation 2000 102 2842 8
23. Sherman-Weber S, Axelrod P, Suh B, Infective endocarditis following orthotopic heart transplantation: 10 cases and a review of the literature. Transpl Infect Dis 2004 6 165 70
24. Lockhart PB, Brennan MT, Sasser HC, Fox PC, Paster BJ, Bahrani-Mougeot FK, Bacteremia associated with toothbrushing and dental extraction. Circulation 2008 117 3118 25
25. Geist SM, Fitzpatrick S, Geist JR, American Heart Association 2007 guidelines on prevention of infective endocarditis. J Mich Dent Assoc 2007 89 50 6
26. Duval X, Alla F, Hoen B, Estimated risk of endocarditis in adults with predisposing cardiac conditions undergoing dental procedures with or without antibiotic prophylaxis. Clin Infect Dis 2006 42 e102 7
27. The 2015 ESC Guidelines for the management of infective endocarditis. Eur Heart J 2015 36 3036 7
28. Horstkotte D, Rosen H, Friedrichs W, Loogen F, Contribution for choosing the optimal prophylaxis of bacterial endocarditis. Eur Heart J 1987 8 suppl J 379 81
29. Strom BL, Abrutyn E, Berlin JA, Dental and cardiac risk factors for infective endocarditis. A population-based, case-control study. Ann Intern Med 1998 129 761 9
30. Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, Infective endocarditis after transcatheter aortic valve implantation: results from a large multicenter registry. Circulation 2015 131 1566 74
31. Mangner N, Woitek F, Haussig S, Incidence, predictors, and outcome of patients developing infective endocarditis following transfemoral transcatheter aortic valve replacement. J Am Coll Cardiol 2016 67 2907 8
32. Karavas AN, Filsoufi F, Mihaljevic T, Aranki SF, Cohn LH, Byrne JG, Risk factors and management of endocarditis after mitral valve repair. J Heart Valve Dis 2002 11 660 4
33. Gillinov AM, Faber CN, Sabik JF, Endocarditis after mitral valve repair. Ann Thorac Surg 2002 73 1813 6
34. Pérez-Gómez F, Alegría E, Berjón J, Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004 44 1557 66
35. Noseworthy PA, Yao X, Shah ND, Gersh BJ, Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. Int J Cardiol 2016 209 181 3
36. Avezum A, Lopes RD, Schulte PJ, Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. Circulation 2015 132 624 32
37. Breithardt G, Baumgartner H, Berkowitz SD, Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J 2014 35 3377 85
38. Ezekowitz MD, Nagarakanti R, Noack H, Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). Circulation 2016 134 589 98
39. Aguilar MI, Hart R, Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2005 CD001927
40. Olesen JB, Lip GY.H, Hansen ML, Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011 342 d124
41. Lytvyn L, Guyatt GH, Manja V, Patient values and preferences on transcatheter or surgical aortic valve replacement therapy for aortic stenosis: a systematic review. BMJ Open 2016 6 e014327
42. Horstkotte D, Loogen F, The natural history of aortic valve stenosis. Eur Heart J 1988 9 Suppl E 57 64
43. O'Brien SM, Shahian DM, Filardo G, The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 2-isolated valve surgery. Ann Thorac Surg 2009 88 S23 42
44. Freeman RV, Otto CM, Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 2005 111 3316 26
45. Kvidal P, Bergström R, Hörte LG, Stahle E, Observed and relative survival after aortic valve replacement. J Am Coll Cardiol 2000 35 747 56
46. Murphy ES, Lawson RM, Starr A, Rahimtoola SH. Severe aortic stenosis in patients 60 years of age or older: left ventricular function and 10-year survival after valve replacement. Circulation 1981 64 II184 8
47. Rosenhek R, Arotic stenosis: disease severity, progression, timing of intervention and role in monitoring transcatheter valve implanation. C.M OttoThe Practice of Clinical Echocardiography 2012 4 ed Philadelphia Elsevier/Saunders PA425 49
48. Schwarz F, Baumann P, Manthey J, The effect of aortic valve replacement on survival. Circulation 1982 66 1105 10
49. Adams DH, Popma JJ, Reardon MJ, Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med 2014 370 1790 8
50. Mack MJ, Leon MB, Smith CR, 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 2015 385 2477 84
51. Deeb GM, Reardon MJ, Chetcuti S, Three-year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol 2016 67 2565 74
52. Holmes DR Jr, Nishimura RA, Grover FL, Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. J Am Coll Cardiol 2015 66 2813 23
53. Makkar RR, Fontana GP, Jilaihawi H, Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med 2012 366 1696 704
54. Smith CR, Leon MB, Mack MJ, Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011 364 2187 98
55. Eltchaninoff H, Prat A, Gilard M, Transcatheter aortic valve implantation: early results of the FRANCE (FRench Aortic National CoreValve and Edwards) registry. Eur Heart J 2011 32 191 7
56. Rodés-Cabau J, Webb JG, Cheung A, Long-term outcomes after transcatheter aortic valve implantation: insights on prognostic factors and valve durability from the Canadian multicenter experience. J Am Coll Cardiol 2012 60 1864 75
57. Abdel-Wahab M, Neumann FJ, Mehilli J, One-year outcomes after transcatheter aortic valve replacement with balloon-expandable versus self-expandable valves: results from the CHOICE randomized clinical trial. J Am Coll Cardiol 2015 66 791 800
58. Kapadia SR, Leon MB, Makkar RR, 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet 2015 385 2485 91
59. Popma JJ, Adams DH, Reardon MJ, Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. J Am Coll Cardiol 2014 63 1972 81
60. Leon MB, Smith CR, Mack M, Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010 363 1597 607
61. Kodali SK, Williams MR, Smith CR, Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med 2012 366 1686 95
62. Leon MB, Smith CR, Mack MJ, Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016 374 1609 20
63. Thourani VH, Kodali S, Makkar RR, Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet 2016 387 2218 25
64. Siemieniuk RA, Agoritsas T, Manja V, Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-Analysis. BMJ 2016 356 i5130
65. Foroutan F, Guyatt GH, O'Brien K, Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies. BMJ 2016 354 i5065
66. Vandvik PO, Otto CM, Siemieniuk RA, Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: a clinical practice guideline. BMJ 2016 354 i5085
67. Uretsky S, Gillam L, Lang R, Discordance between echocardiography and MRI in the assessment of mitral regurgitation severity: a prospective multicenter trial. J Am Coll Cardiol 2015 65 1078 88
68. Grayburn PA, Carabello B, Hung J, Defining "severe" secondary mitral regurgitation: emphasizing an integrated approach. J Am Coll Cardiol 2014 64 2792 801
69. Acker MA, Parides MK, Perrault LP, Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 2014 370 23 32
70. Goldstein D, Moskowitz AJ, Gelijns AC, Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. N Engl J Med 2016 374 344 53
71. Michler RE, Smith PK, Parides MK, Two-year outcomes of surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2016 374 1932 41
72. Smith PK, Puskas JD, Ascheim DD, Surgical treatment of moderate ischemic mitral regurgitation. N Engl J Med 2014 371 2178 88
73. David TE, Armstrong S, McCrindle BW, Manlhiot C, Late outcomes of mitral valve repair for mitral regurgitation due to degenerative disease. Circulation 2013 127 1485 92
74. Gillinov AM, Mihaljevic T, Blackstone EH, Should patients with severe degenerative mitral regurgitation delay surgery until symptoms develop? Ann Thorac Surg 2010 90 481 8
75. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Impact of preoperative symptoms on survival after surgical correction of organic mitral regurgitation: rationale for optimizing surgical indications. Circulation 1999 99 400 5
76. Crawford MH, Souchek J, Oprian CA, Determinants of survival and left ventricular performance after mitral valve replacement. Department of Veterans Affairs Cooperative Study on Valvular Heart Disease. Circulation 1990 81 1173 81
77. Enriquez-Sarano M, Tajik AJ, Schaff HV, Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol 1994 24 1536 43
78. Grigioni F, Enriquez-Sarano M, Ling LH, Sudden death in mitral regurgitation due to flail leaflet. J Am Coll Cardiol 1999 34 2078 85
79. Grigioni F, Tribouilloy C, Avierinos JF, Outcomes in mitral regurgitation due to flail leaflets a multicenter European study. J Am Coll Cardiol Img 2008 1 133 41
80. Schuler G, Peterson KL, Johnson A, Temporal response of left ventricular performance to mitral valve surgery. Circulation 1979 59 1218 31
81. Starling MR, Effects of valve surgery on left ventricular contractile function in patients with long-term mitral regurgitation. Circulation 1995 92 811 8
82. Tribouilloy C, Grigioni F, Avierinos JF, Survival implication of left ventricular end-systolic diameter in mitral regurgitation due to flail leaflets a long-term follow-up multicenter study. J Am Coll Cardiol 2009 54 1961 8
83. STS online risk calculator. Available at: http://riskcalcstsorg/stswebriskcalc Accessed January 20, 2017
84. Braunberger E, Deloche A, Berrebi A, Very long-term results (more than 20 years) of valve repair with Carpentier's techniques in nonrheumatic mitral valve insufficiency. Circulation 2001 104 I8 1
85. Cohn LH, Surgery for mitral regurgitation. JAMA 1988 260 2883 7
86. Cosgrove DM, Chavez AM, Lytle BW, Results of mitral valve reconstruction. Circulation 1986 74 I82 7
87. David TE, Uden DE, Strauss HD, The importance of the mitral apparatus in left ventricular function after correction of mitral regurgitation. Circulation 1983 68 II76 82
88. David TE, Burns RJ, Bacchus CM, Druck MN, Mitral valve replacement for mitral regurgitation with and without preservation of chordae tendineae. J Thorac Cardiovasc Surg 1984 88 718 25
89. David TE, Ivanov J, Armstrong S, Christie D, Rakowski H, A comparison of outcomes of mitral valve repair for degenerative disease with posterior, anterior, and bileaflet prolapse. J Thorac Cardiovasc Surg 2005 130 1242 9
90. Gammie JS, Sheng S, Griffith BP, Trends in mitral valve surgery in the United States: results from the Society of Thoracic Surgeons Adult Cardiac Surgery Database. Ann Thorac Surg 2009 87 1431 7. discussion 7-349
91. Goldman KE, Dental management of patients with bone marrow and solid organ transplantation. Dent Clin North Am 2006 50 659 76viii
92. Hansen DE, Sarris GE, Niczyporuk MA, Derby GC, Cahill PD, Miller DC, Physiologic role of the mitral apparatus in left ventricular regional mechanics, contraction synergy, and global systolic performance. J Thorac Cardiovasc Surg 1989 97 521 33
93. Hennein HA, Swain JA, McIntosh CL, Bonow RO, Stone CD, Clark RE, Comparative assessment of chordal preservation versus chordal resection during mitral valve replacement. J Thorac Cardiovasc Surg 1990 99 828 36. discussion 36-7
94. Horskotte D, Schulte HD, Bircks W, Strauer BE, The effect of chordal preservation on late outcome after mitral valve replacement: a randomized study. J Heart Valve Dis 1993 2 150 8
95. McClure RS, Athanasopoulos LV, McGurk S, Davidson MJ, Couper GS, Cohn LH, One thousand minimally invasive mitral valve operations: early outcomes, late outcomes, and echocardiographic follow-up. J Thorac Cardiovasc Surg 2013 145 1199 206
96. Rozich JD, Carabello BA, Usher BW, Kratz JM, Bell AE, Zile MR, Mitral valve replacement with and without chordal preservation in patients with chronic mitral regurgitation. Mechanisms for differences in postoperative ejection performance. Circulation 1992 86 1718 26
97. Rushmer RF, Initial phase of ventricular systole: asynchronous contraction. Am J Physiol 1956 184 188 94
98. Sarris GE, Cahill PD, Hansen DE, Derby GC, Miller DC, Restoration of left ventricular systolic performance after reattachment of the mitral chordae tendineae. The importance of valvular-ventricular interaction. J Thorac Cardiovasc Surg 1988 95 969 79
99. Vassileva CM, Mishkel G, McNeely C, Long-term survival of patients undergoing mitral valve repair and replacement: a longitudinal analysis of Medicare fee-for-service beneficiaries. Circulation 2013 127 1870 6
100. Badhwar V, Peterson ED, Jacobs JP, Longitudinal outcome of isolated mitral repair in older patients: results from 14,604 procedures performed from 1991 to 2007. Ann Thorac Surg 2012 94 1870 9
101. Bolling SF, Li S, O'Brien SM, Brennan JM, Prager RL, Gammie JS, Predictors of mitral valve repair: clinical and surgeon factors. Ann Thorac Surg 2010 90 1904 11. discussion 12
102. Chauvaud S, Fuzellier JF, Berrebi A, Deloche A, Fabiani JN, Carpentier A, Long-term (29 years) results of reconstructive surgery in rheumatic mitral valve insufficiency. Circulation 2001 104 I12 5
103. Chikwe J, Goldstone AB, Passage J, A propensity score-Adjusted retrospective comparison of early and mid-term results of mitral valve repair versus replacement in octogenarians. Eur Heart J 2011 32 618 26
104. Grossi EA, Galloway AC, Miller JS, Valve repair versus replacement for mitral insufficiency: when is a mechanical valve still indicated?. J Thorac Cardiovasc Surg 1998 115 389 96
105. Gillinov AM, Blackstone EH, Cosgrove DM, Mitral valve repair with aortic valve replacement is superior to double valve replacement. J Thorac Cardiovasc Surg 2003 125 1372 87
106. Suri RM, Vanoverschelde JL, Grigioni F, Association between early surgical intervention vs watchful waiting and outcomes for mitral regurgitation due to flail mitral valve leaflets. JAMA 2013 310 609 16
107. Rosenhek R, Rader F, Klaar U, Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006 113 2238 44
108. Gillinov AM, Blackstone EH, Nowicki ER, Valve repair versus valve replacement for degenerative mitral valve disease. J Thorac Cardiovasc Surg 2008 135 885 9393.e1-2
109. Duran CM, Gometza B, Saad E, Valve repair in rheumatic mitral disease: an unsolved problem. J Card Surg 1994 9 282 5
110. Suri RM, Schaff HV, Dearani JA, Recovery of left ventricular function after surgical correction of mitral regurgitation caused by leaflet prolapse. J Thorac Cardiovasc Surg 2009 137 1071 6
111. Kang DH, Kim JH, Rim JH, Comparison of early surgery versus conventional treatment in asymptomatic severe mitral regurgitation. Circulation 2009 119 797 804
112. Tribouilloy C, Rusinaru D, Szymanski C, Predicting left ventricular dysfunction after valve repair for mitral regurgitation due to leaflet prolapse: additive value of left ventricular end-systolic dimension to ejection fraction. Eur J Echocardiogr 2011 112 702 10
113. Enriquez-Sarano M, Suri RM, Clavel MA, Is there an outcome penalty linked to guideline-based indications for valvular surgery? Early and long-term analysis of patients with organic mitral regurgitation. J Thorac Cardiovasc Surg 2015 150 50 8
114. Quintana E, Suri RM, Thalji NM, Left ventricular dysfunction after mitral valve repair-The fallacy of "normal" preoperative myocardial function. J Thorac Cardiovasc Surg 2014 148 2752 60
115. Suri RM, Schaff HV, Dearani JA, Determinants of early decline in ejection fraction after surgical correction of mitral regurgitation. J Thorac Cardiovasc Surg 2008 136 442 7
116. Naji P, Griffin BP, Barr T, Importance of exercise capacity in predicting outcomes and determining optimal timing of surgery in significant primary mitral regurgitation. J Am Heart Assoc 2014 3 e001010
117. Cox JL, The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg 1991 101 584 92
118. Ghoreishi M, Evans CF, DeFilippi CR, Pulmonary hypertension adversely affects short-and long-term survival after mitral valve operation for mitral regurgitation: implications for timing of surgery. J Thorac Cardiovasc Surg 2011 142 1439 52
119. Kawaguchi AT, Kosakai Y, Sasako Y, Eishi K, Nakano K, Kawashima Y, Risks and benefits of combined maze procedure for atrial fibrillation associated with organic heart disease. J Am Coll Cardiol 1996 28 985 90
120. Kobayashi J, Kosakai Y, Isobe F, Rationale of the Cox Maze procedure for atrial fibrillation during redo mitral valve operations. J Thorac Cardiovasc Surg 1996 112 1216 21. discussion 22
121. Ngaage DL, Schaff HV, Mullany CJ, Influence of preoperative atrial fibrillation on late results of mitral repair: is concomitant ablation justified?. Ann Thorac Surg 2007 84 434 42. discussion 42-3
122. Olasinska-Wisniewska A, Mularek-Kubzdela T, Grajek S, Impact of atrial remodeling on heart rhythm after radiofrequency ablation and mitral valve operations. Ann Thorac Surg 2012 93 1449 55
123. Raine D, Dark J, Bourke JP, Effect of mitral valve repair/replacement surgery on atrial arrhythmia behavior. J Heart Valve Dis 2004 13 615 21
124. Feldman T, Foster E, Glower DD, Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011 364 1395 406
125. Fattouch K, Guccione F, Sampognaro R, POINT: Efficacy of adding mitral valve restrictive annuloplasty to coronary artery bypass grafting in patients with moderate ischemic mitral valve regurgitation: a randomized trial. J Thorac Cardiovasc Surg 2009 364 278 85
126. Whitlow PL, Feldman T, Pedersen WR, Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol 2012 59 130 9
127. Wu AH, Aaronson KD, Bolling SF, Pagani FD, Welch K, Koelling TM, Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunction. J Am Coll Cardiol 2005 45 381 7
128. Asgar AW, Mack MJ, Stone GW, Secondary mitral regurgitation in heart failure: pathophysiology, prognosis, and therapeutic considerations. J Am Coll Cardiol 2015 65 1231 48
129. Obadia JF, Armoiry X, Iung B, The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation. EuroIntervention 2015 10 1354 60
130. Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ, Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001 103 1759 64
131. Lancellotti P, Gérard PL, Piérard LA, Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J 2005 26 1528 32
132. Trichon BH, Felker GM, Shaw LK, Cabell CH, O'Connor CM, Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. Am J Cardiol 2003 91 538 43
133. Rossi A, Dini FL, Faggiano P, Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 2011 97 1675 80
134. Mihaljevic T, Lam BK, Rajeswaran J, Impact of mitral valve annuloplasty combined with revascularization in patients with functional ischemic mitral regurgitation. J Am Coll Cardiol 2007 49 2191 201
135. Harris KM, Sundt TM, Aeppli D, Sharma R, Barzilai B, Can late survival of patients with moderate ischemic mitral regurgitation be impacted by intervention on the valve?. Ann Thorac Surg 2002 74 1468 75
136. Benedetto U, Melina G, Roscitano A, Does combined mitral valve surgery improve survival when compared to revascularization alone in patients with ischemic mitral regurgitation? A meta-Analysis on 2479 patients. J Cardiovasc Med (Hagerstown) 2009 10 109 14
137. Deja MA, Grayburn PA, Sun B, Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. Circulation 2012 125 2639 48
138. Cohn LH, Rizzo RJ, Adams DH, The effect of pathophysiology on the surgical treatment of ischemic mitral regurgitation: operative and late risks of repair versus replacement. Eur J Cardiothorac Surg 1995 9 568 74
139. Chan KMJ, Punjabi PP, Flather M, Coronary artery bypass surgery with or without mitral valve annuloplasty in moderate functional ischemic mitral regurgitation: final results of the Randomized Ischemic Mitral Evaluation (RIME) trial. Circulation 2012 126 2502 10
140. Lim DS, Reynolds MR, Feldman T, Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol 2013 64 182 92
141. van Geldorp MW.A, Eric Jamieson WR, Kappetein AP, Patient outcome after aortic valve replacement with a mechanical or biological prosthesis: weighing lifetime anticoagulant-related event risk against reoperation risk. J Thorac Cardiovasc Surg 2009 137 881 66e1-5
142. Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U, Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50-69 years. Eur Heart J 2016 37 2658 67
143. Chikwe J, Chiang YP, Egorova NN, Itagaki S, Adams DH, Survival and outcomes following bioprosthetic vs mechanical mitral valve replacement in patients aged 50 to 69 years. JAMA 2015 313 1435 42
144. McClure RS, McGurk S, Cevasco M, Late outcomes comparison of nonelderly patients with stented bioprosthetic and mechanical valves in the aortic position: a propensity-matched analysis. J Thorac Cardiovasc Surg 2014 148 1931 9
145. Chiang YP, Chikwe J, Moskowitz AJ, Itagaki S, Adams DH, Egorova NN, Survival and long-term outcomes following bioprosthetic vs mechanical aortic valve replacement in patients aged 50 to 69 years. JAMA 2014 312 1323 9
146. Repack A, Ziganshin BA, Elefteriades JA, Mukherjee SK, Comparison of quality of life perceived by patients with bioprosthetic versus mechanical valves after composite aortic root replacement. Cardiology 2016 133 3 9
147. Dunning J, Gao H, Chambers J, Aortic valve surgery: marked increases in volume and significant decreases in mechanical valve use-An analysis of 41,227 patients over 5 years from the Society for Cardiothoracic Surgery in Great Britain and Ireland National database. J Thorac Cardiovasc Surg 2011 142 776 82.e3
148. Rahimtoola SH, Choice of prosthetic heart valve in adults an update. J Am Coll Cardiol 2010 55 2413 26
149. Weber A, Noureddine H, Englberger L, Ten-year comparison of pericardial tissue valves versus mechanical prostheses for aortic valve replacement in patients younger than 60 years of age. J Thorac Cardiovasc Surg 2012 144 1075 83
150. Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg 2015 99 831 7
151. Bourguignon T, Bouquiaux-Stablo AL, Loardi C, Very late outcomes for mitral valve replacement with the Carpentier-Edwards pericardial bioprosthesis: 25-year follow-up of 450 implantations. J Thorac Cardiovasc Surg 2014 148 2004 11.e1
152. Ye J, Cheung A, Yamashita M, Transcatheter aortic and mitral valve-in-valve implantation for failed surgical bioprosthetic valves: an eight-year single-center experience. J Am Coll Cardiol Intv 2015 8 1735 44
153. Dvir D, Webb J, Brecker S, Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation 2012 126 2335 44
154. Dvir D, Webb JG, Bleiziffer S, Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA 2014 312 162 70
155. Hammermeister K, Sethi GK, Henderson WG, Grover FL, Oprian C, Rahimtoola SH, Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000 36 1152 8
156. Chan V, Jamieson WR.E, Germann E, Performance of bioprostheses and mechanical prostheses assessed by composites of valve-related complications to 15 years after aortic valve replacement. J Thorac Cardiovasc Surg 2006 131 1267 73
157. Kaneko T, Aranki S, Javed Q, Mechanical versus bioprosthetic mitral valve replacement in patients <65 years old. J Thorac Cardiovasc Surg 2014 147 117 26
158. Badhwar V, Ofenloch JC, Rovin JD, van Gelder HM, Jacobs JP, Noninferiority of closely monitored mechanical valves to bioprostheses overshadowed by early mortality benefit in younger patients. Ann Thorac Surg 2012 93 748 53
159. Brown ML, Schaff HV, Lahr BD, Aortic valve replacement in patients aged 50 to 70 years: improved outcome with mechanical versus biologic prostheses. J Thorac Cardiovasc Surg 2008 135 878 84. discussion 84
160. Kulik A, Bédard P, Lam BK, Mechanical versus bioprosthetic valve replacement in middle-Aged patients. Eur J Cardiothorac Surg 2006 30 485 91
161. Bourguignon T, El Khoury R, Candolfi P, Very long-term outcomes of the Carpentier-Edwards Perimount aortic valve in patients aged 60 or younger. Ann Thorac Surg 2015 100 853 9
162. McClure RS, Narayanasamy N, Wiegerinck E, Late outcomes for aortic valve replacement with the Carpentier-Edwards pericardial bioprosthesis: up to 17-year follow-up in 1,000 patients. Ann Thorac Surg 2010 89 1410 6
163. Banbury MK, Cosgrove DM, Thomas JD, Hemodynamic stability during 17 years of the Carpentier-Edwards aortic pericardial bioprosthesis. Ann Thorac Surg 2002 73 1460 5
164. Borger MA, Ivanov J, Armstrong S, Christie-Hrybinsky D, Feindel CM, David TE, Twenty-year results of the Hancock II bioprosthesis. J Heart Valve Dis 2006 15 49 55. discussion 6
165. Dellgren G, David TE, Raanani E, Armstrong S, Ivanov J, Rakowski H, Late hemodynamic and clinical outcomes of aortic valve replacement with the Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg 2002 124 146 54
166. Mykén PS, Bech-Hansen O, A 20-year experience of 1712 patients with the Biocor porcine bioprosthesis. J Thorac Cardiovasc Surg 2009 137 76 81
167. Charitos EI, Takkenberg JJ.M, Hanke T, Reoperations on the pulmonary autograft and pulmonary homograft after the Ross procedure: an update on the German Dutch Ross Registry. J Thorac Cardiovasc Surg 2012 144 813 21. discussion 21-3
168. El-Hamamsy I, Eryigit Z, Stevens LM, Long-term outcomes after autograft versus homograft aortic root replacement in adults with aortic valve disease: a randomised controlled trial. Lancet 2010 376 524 31
169. Mokhles MM, Rizopoulos D, Andrinopoulou ER, Autograft and pulmonary allograft performance in the second post-operative decade after the Ross procedure: insights from the Rotterdam Prospective Cohort Study. Eur Heart J 2012 33 2213 24
170. Edmunds LH Jr., Thrombotic and bleeding complications of prosthetic heart valves. Ann Thorac Surg 1987 44 430 45
171. Tiede DJ, Nishimura RA, Gastineau DA, Mullany CJ, Orszulak TA, Schaff HV, Modern management of prosthetic valve anticoagulation. Mayo Clin Proc 1998 73 665 80
172. Aziz F, Corder M, Wolffe J, Comerota AJ, Anticoagulation monitoring by an anticoagulation service is more cost-effective than routine physician care. J Vasc Surg 2011 54 1404 7
173. Chiquette E, Amato MG, Bussey HI, Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998 158 1641 7
174. Wittkowsky AK, Nutescu EA, Blackburn J, Outcomes of oral anticoagulant therapy managed by telephone vs in-office visits in an anticoagulation clinic setting. Chest 2006 134 1385 9
175. Lalonde L, Martineau J, Blais N, Is long-term pharmacist-managed anticoagulation service efficient? A pragmatic randomized controlled trial. Am Heart J 2008 156 148 54
176. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ, Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005 127 1515 22
177. Locke C, Ravnan SL, Patel R, Uchizono JA, Reduction in warfarin adverse events requiring patient hospitalization after implementation of a pharmacist-managed anticoagulation service. Pharmacotherapy 2005 25 685 9
178. Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH, Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis. Chest 2012 141 9th ed American College of Chest Physicians Evidence-Based Clinical Practice Guidelines e576S 600
179. Cannegieter SC, Rosendaal FR, Briët E, Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994 89 635 41
180. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995 333 11 7
181. Schlitt A, von Bardeleben RS, Ehrlich A, Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thromb Res 2003 109 131 5
182. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG, Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001 119 220S 7S
183. Sun JCJ, Davidson MJ, Lamy A, Eikelboom JW, Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 2009 374 565 76
184. Acar J, Iung B, Boissel JP, AREVA: multicenter randomized comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996 94 2107 12
185. Hering D, Piper C, Bergemann R, Thromboembolic and bleeding complications following St. Jude Medical valve replacement: results of the German Experience With Low-Intensity Anticoagulation Study. Chest 2005 127 53 9
186. Torella M, Torella D, Chiodini P, LOWERing the INtensity of oral anticoaGulant Therapy in patients with bileaflet mechanical aortic valve replacement: results from the "LOWERING-IT" Trial. Am Heart J 2010 160 171 8
187. Horstkotte D, Scharf RE, Schultheiss HP, Intracardiac thrombosis: patient-related and device-related factors. J Heart Valve Dis 1995 4 114 20
188. Pruefer D, Dahm M, Dohmen G, Horstkotte D, Bergemann R, Oelert H, Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5). Eur Heart J 2001 Suppl 3 Suppl Q Q39 43
189. Meschengieser SS, Fondevila CG, Frontroth J, Santarelli MT, Lazzari MA, Low-intensity oral anticoagulation plus low-dose aspirin versus high-intensity oral anticoagulation alone: a randomized trial in patients with mechanical prosthetic heart valves. J Thorac Cardiovasc Surg 1997 113 910 6
190. Turpie AG, Gent M, Laupacis A, A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. N Engl J Med 1993 329 524 9
191. Aramendi JI, Mestres CA, Campos V, Martinez-Leon J, Munoz G, Navas C, Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (trac): prospective, randomized, co-operative trial. Eur J Cardiothorac Surg 2005 27 854 60
192. Colli A, Mestres CA, Castella M, Gherli T, Comparing warfarin to aspirin (WoA) after aortic valve replacement with the St. Jude Medical Epic heart valve bioprosthesis: results of the WoA Epic pilot trial. J Heart Valve Dis 2007 16 667 71
193. Heras M, Chesebro JH, Fuster V, High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995 25 1111 9
194. Nuñez L, Gil Aguado M, Larrea JL, Celemin D, Oliver J, Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thorac Surg 1984 37 84 7
195. Brennan JM, Edwards FH, Zhao Y, Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012 60 971 7
196. Egbe AC, Pislaru SV, Pellikka PA, Bioprosthetic valve thrombosis versus structural failure: clinical and echocardiographic predictors. J Am Coll Cardiol 2015 66 2285 94
197. Mérie C, Køber L, Skov Olsen P, Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA 2012 308 2118 25
198. Connolly SJ, Ezekowitz MD, Yusuf S, Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009 361 1139 51
199. Douketis JD, Spyropoulos AC, Kaatz S, Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015 373 823 33
200. Eikelboom JW, Connolly SJ, Brueckmann M, Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013 369 1206 14
201. Giugliano RP, Ruff CT, Braunwald E, Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013 369 2093 104
202. Granger CB, Alexander JH, McMurray JJ.V, Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011 365 981 92
203. Makkar RR, Fontana G, Jilaihawi H, Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 2015 373 2015 24
204. Patel MR, Mahaffey KW, Garg J, Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011 365 883 91
205. Sundt TM, Zehr KJ, Dearani JA, Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement?. J Thorac Cardiovasc Surg 2005 129 1024 31
206. Russo A, Grigioni F, Avierinos JF, Thromboembolic complications after surgical correction of mitral regurgitation incidence, predictors, and clinical implications. J Am Coll Cardiol 2008 51 1203 11
207. ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH, Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm?. J Thorac Cardiovasc Surg 2010 139 1137 45
208. Levine GN, Bates ER, Bittl JA, 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016 134 e123 55
209. Puskas J, Gerdisch M, Nichols D, Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized On-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg 2014 147 1202 10. discussion 10-1
210. Hansson NC, Grove EL, Andersen HR, Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol 2016 68 2059 69
211. Pache G, Schoechlin S, Blanke P, Early hypo-Attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J 2016 37 2263 71
212. FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. 2012. December 19, 2012
213. Van de Werf F, Brueckmann M, Connolly SJ, A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J 2012 163 931 7.e1
214. Douketis JD, Spyropoulos AC, Spencer FA, Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Erratum. Chest 2012 141 e326S 350
215. Pengo V, Palareti G, Cucchini U, Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). Clin Appl Thromb Hemost 2007 13 241 8
216. Barbetseas J, Nagueh SF, Pitsavos C, Toutouzas PK, Quinones MA, Zoghbi WA, Differentiating thrombus from pannus formation in obstructed mechanical prosthetic valves: an evaluation of clinical, transthoracic and transesophageal echocardiographic parameters. J Am Coll Cardiol 1998 32 1410 7
217. Gündüz S, özkan M, Kalçik M, Sixty-four-section cardiac computed tomography in mechanical prosthetic heart valve dysfunction: thrombus or pannus. Circ Cardiovasc Imaging 2015 8 e003246
218. Cianciulli TE, Lax JA, Beck MA, Cinefluoroscopic assessment of mechanical disc prostheses: its value as a complementary method to echocardiography. J Heart Valve Dis 2005 14 664 73
219. Montorsi P, De Bernardi F, Muratori M, Cavoretto D, Pepi M, Role of cine-fluoroscopy, transthoracic, and transesophageal echocardiography in patients with suspected prosthetic heart valve thrombosis. Am J Cardiol 2000 85 58 64
220. Muratori M, Montorsi P, Teruzzi G, Feasibility and diagnostic accuracy of quantitative assessment of mechanical prostheses leaflet motion by transthoracic and transesophageal echocardiography in suspected prosthetic valve dysfunction. Am J Cardiol 2006 97 94 100
221. Suh YJ, Lee S, Im DJ, Added value of cardiac computed tomography for evaluation of mechanical aortic valve: emphasis on evaluation of pannus with surgical findings as standard reference. Int J Cardiol 2016 214 454 60
222. Symersky P, Budde RPJ, de Mol BAJM, Prokop M, Comparison of multidetector-row computed tomography to echocardiography and fluoroscopy for evaluation of patients with mechanical prosthetic valve obstruction. Am J Cardiol 2009 104 1128 34
223. Gürsoy OM, Karakoyun S, Kalçik M, Ozkan M, The incremental value of RT three-dimensional TEE in the evaluation of prosthetic mitral valve ring thrombosis complicated with thromboembolism. Echocardiography 2013 30 E198 201
224. Tong AT, Roudaut R, özkan M, Transesophageal echocardiography improves risk assessment of thrombolysis of prosthetic valve thrombosis: results of the international PRO-TEE registry. J Am Coll Cardiol 2004 43 77 84
225. Keuleers S, Herijgers P, Herregods MC, Comparison of thrombolysis versus surgery as a first line therapy for prosthetic heart valve thrombosis. Am J Cardiol 2011 107 275 9
226. Roudaut R, Lafitte S, Roudaut MF, Management of prosthetic heart valve obstruction: fibrinolysis versus surgery. Early results and long-term follow-up in a single-centre study of 263 cases. Arch Cardiovasc Dis 2009 102 269 77
227. Karthikeyan G, Math RS, Mathew N, Accelerated infusion of streptokinase for the treatment of left-sided prosthetic valve thrombosis: a randomized controlled trial. Circulation 2009 120 1108 14
228. Cáceres-Lóriga FM, Pérez-López H, Morlans-Hernandez K, Thrombolysis as first choice therapy in prosthetic heart valve thrombosis. A study of 68 patients. J Thromb Thrombolysis 2006 21 185 90
229. özkan M, Gündüz S, Biteker M, Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. J Am Coll Cardiol Img 2013 6 206 16
230. Nagy A, Dénes M, Lengyel M, Predictors of the outcome of thrombolytic therapy in prosthetic mitral valve thrombosis: a study of 62 events. J Heart Valve Dis 2009 18 268 75
231. özkan M, çakal B, Karakoyun S, Thrombolytic therapy for the treatment of prosthetic heart valve thrombosis in pregnancy with low-dose, slow infusion of tissue-type plasminogen activator. Circulation 2013 128 532 40
232. Deviri E, Sareli P, Wisenbaugh T, Cronje SL, Obstruction of mechanical heart valve prostheses: clinical aspects and surgical management. J Am Coll Cardiol 1991 17 646 50
233. Karthikeyan G, Senguttuvan NB, Joseph J, Devasenapathy N, Bahl VK, Airan B, Urgent surgery compared with fibrinolytic therapy for the treatment of left-sided prosthetic heart valve thrombosis: a systematic review and meta-Analysis of observational studies. Eur Heart J 2013 34 1557 66
234. Huang G, Schaff HV, Sundt TM, Rahimtoola SH, Treatment of obstructive thrombosed prosthetic heart valve. J Am Coll Cardiol 2013 62 1731 6
235. Özkan M, Gündüz S, Gürsoy OM, Ultraslow thrombolytic therapy: a novel strategy in the management of PROsthetic MEchanical valve Thrombosis and the prEdictors of outcomE: The Ultra-slow PROMETEE trial. Am Heart J 2015 170 409 18
236. Laschinger JC, Wu C, Ibrahim NG, Shuren JE, Reduced leaflet motion in bioprosthetic aortic valves-The FDA perspective. N Engl J Med 2015 373 1996 8
237. Pibarot P, Dumesnil JG, Prosthetic heart valves: selection of the optimal prosthesis and long-term management. Circulation 2009 119 1034 48
238. Koene BM, Soliman Hamad MA, Bouma W, Impact of prosthesis-patient mismatch on early and late mortality after aortic valve replacement. J Cardiothorac Surg 2013 8 96
239. Maganti M, Rao V, Armstrong S, Feindel CM, Scully HE, David TE, Redo valvular surgery in elderly patients. Ann Thorac Surg 2009 87 521 5
240. Leontyev S, Borger MA, Davierwala P, Redo aortic valve surgery: early and late outcomes. Ann Thorac Surg 2011 91 1120 6
241. Kaneko T, Vassileva CM, Englum B, Contemporary outcomes of repeat aortic valve replacement: a benchmark for transcatheter valve-in-valve procedures. Ann Thorac Surg 2015 100 1298 304. discussion 304
242. Jander N, Kienzle RP, Kayser G, Neumann FJ, Gohlke-Baerwolf C, Minners J, Usefulness of phenprocoumon for the treatment of obstructing thrombus in bioprostheses in the aortic valve position. Am J Cardiol 2012 109 257 62
243. Butnaru A, Shaheen J, Tzivoni D, Tauber R, Bitran D, Silberman S, Diagnosis and treatment of early bioprosthetic malfunction in the mitral valve position due to thrombus formation. Am J Cardiol 2013 112 1439 44
244. Pislaru SV, Hussain I, Pellikka PA, Misconceptions, diagnostic challenges and treatment opportunities in bioprosthetic valve thrombosis: lessons from a case series. Eur J Cardiothorac Surg 2015 47 725 32
245. De Marchena E, Mesa J, Pomenti S, Thrombus formation following transcatheter aortic valve replacement. J Am Coll Cardiol Intv 2015 8 728 39
246. Latib A, Naganuma T, Abdel-Wahab M, Treatment and clinical outcomes of transcatheter heart valve thrombosis. Circ Cardiovasc Interv 2015 8
247. Webb JG, Wood DA, Ye J, Transcatheter valve-in-valve implantation for failed bioprosthetic heart valves. Circulation 2010 121 1848 57
248. Phan K, Zhao DF, Wang N, Huo YR, Di EM, Yan TD, Transcatheter valve-in-valve implantation versus reoperative conventional aortic valve replacement: a systematic review. J Thorac Dis 2016 8 E83 93
249. Administration USFaD FDA expands use of CoreValue System for aortic "valve-in-valve replacement". March 30, 2015. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm440535.htm. Accessed January 20, 2017
250. Akins CW, Bitondo JM, Hilgenberg AD, Vlahakes GJ, Madsen JC, MacGillivray TE, Early and late results of the surgical correction of cardiac prosthetic paravalvular leaks. J Heart Valve Dis 2005 14 792 9. discussion 9-800
251. Miller DL, Morris JJ, Schaff HV, Mullany CJ, Nishimura RA, Orszulak TA, Reoperation for aortic valve periprosthetic leakage: identification of patients at risk and results of operation. J Heart Valve Dis 1995 4 160 5
252. Ruiz CE, Jelnin V, Kronzon I, Clinical outcomes in patients undergoing percutaneous closure of periprosthetic paravalvular leaks. J Am Coll Cardiol 2011 58 2210 7
253. Sorajja P, Cabalka AK, Hagler DJ, Rihal CS, Percutaneous repair of paravalvular prosthetic regurgitation: acute and 30-day outcomes in 115 patients. Circ Cardiovasc Interv 2011 4 314 21
254. Sorajja P, Cabalka AK, Hagler DJ, Rihal CS, Long-term follow-up of percutaneous repair of paravalvular prosthetic regurgitation. J Am Coll Cardiol 2011 58 2218 24
255. Botelho-Nevers E, Thuny F, Casalta JP, Dramatic reduction in infective endocarditis-related mortality with a management-based approach. Arch Intern Med 2009 169 1290 8
256. Gordon SM, Serkey JM, Longworth DL, Lytle BW, Cosgrove DM., Early onset prosthetic valve endocarditis: the Cleveland Clinic experience 1992-1997. Ann Thorac Surg 2000 69 1388 92
257. Hasbun R, Vikram HR, Barakat LA, Buenconsejo J, Quagliarello VJ, Complicated left-sided native valve endocarditis in adults: risk classification for mortality. JAMA 2003 289 1933 40
258. Jault F, Gandjbakhch I, Rama A, Active native valve endocarditis: determinants of operative death and late mortality. Ann Thorac Surg 1997 63 1737 41
259. Kiefer T, Park L, Tribouilloy C, Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. JAMA 2011 306 2239 47
260. Tornos P, Sanz E, Permanyer-Miralda G, Almirante B, Planes AM, Soler-Soler J, Late prosthetic valve endocarditis. Immediate and long-term prognosis. Chest 1992 101 37 41
261. Wang A, Athan E, Pappas PA, Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 2007 297 1354 61
262. Aksoy O, Sexton DJ, Wang A, Early surgery in patients with infective endocarditis: a propensity score analysis. Clin Infect Dis 2007 44 364 72
263. Chirouze C, Cabell CH, Fowler VG Jr, Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration on Endocarditis merged database. Clin Infect Dis 2004 38 1323 7
264. Ellis ME, Al-Abdely H, Sandridge A, Greer W, Ventura W, Fungal endocarditis: evidence in the world literature, 1965-1995. Clin Infect Dis 2001 32 50 62
265. Hill EE, Herijgers P, Claus P, Vanderschueren S, Herregods MC, Peetermans WE, Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. Eur Heart J 2007 28 196 203
266. Melgar GR, Nasser RM, Gordon SM, Lytle BW, Keys TF, Longworth DL, Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine (Baltimore) 1997 76 94 103
267. Remadi JP, Habib G, Nadji G, Predictors of death and impact of surgery in Staphylococcus aureus infective endocarditis. Ann Thorac Surg 2007 83 1295 302
268. Wolff M, Witchitz S, Chastang C, Regnier B, Vachon F, Prosthetic valve endocarditis in the ICU. Prognostic factors of overall survival in a series of 122 cases and consequences for treatment decision. Chest 1995 108 688 94
269. Anguera I, Miro JM, Vilacosta I, Aorto-cavitary fistulous tract formation in infective endocarditis: clinical and echocardiographic features of 76 cases and risk factors for mortality. Eur Heart J 2005 26 288 97
270. Chan KL, Early clinical course and long-term outcome of patients with infective endocarditis complicated by perivalvular abscess. CMAJ 2002 167 19 24
271. Jault F, Gandjbakhch I, Chastre JC, Prosthetic valve endocarditis with ring abscesses. Surgical management and long-term results. J Thorac Cardiovasc Surg 1993 105 1106 13
272. Middlemost S, Wisenbaugh T, Meyerowitz C, A case for early surgery in native left-sided endocarditis complicated by heart failure: results in 203 patients. J Am Coll Cardiol 1991 18 663 7
273. Wang K, Gobel F, Gleason DF, Edwards JE, Complete heart block complicating bacterial endocarditis. Circulation 1972 46 939 47
274. Hill EE, Herijgers P, Claus P, Vanderschueren S, Peetermans WE, Herregods MC, Abscess in infective endocarditis: the value of transesophageal echocardiography and outcome: a 5-year study. Am Heart J 2007 154 923 8
275. Klieverik LMA, Yacoub MH, Edwards S, Surgical treatment of active native aortic valve endocarditis with allografts and mechanical prostheses. Ann Thorac Surg 2009 88 1814 21
276. Manne MB, Shrestha NK, Lytle BW, Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg 2012 93 489 93
277. Athan E, Chu VH, Tattevin P, Clinical characteristics and outcome of infective endocarditis involving implantable cardiac devices. JAMA 2012 307 1727 35
278. Ho HH, Siu CW, Yiu KH, Tse HF, Chui WH, Chow WH, Prosthetic valve endocarditis in a multicenter registry of Chinese patients. Asian Cardiovasc Thorac Ann 2010 18 430 4
279. Rundström H, Kennergren C, Andersson R, Alestig K, Hogevik H, Pacemaker endocarditis during 18 years in Göteborg. Scand J Infect Dis 2004 36 674 9
280. Sohail MR, Uslan DZ, Khan AH, Infective endocarditis complicating permanent pacemaker and implantable cardioverter-defibrillator infection. Mayo Clin Proc 2008 83 46 53
281. Kang DH, Kim YJ, Kim SH, Early surgery versus conventional treatment for infective endocarditis. N Engl J Med 2012 366 2466 73
282. Mügge A, Daniel WG, Frank G, Lichtlen PR, Echocardiography in infective endocarditis: reassessment of prognostic implications of vegetation size determined by the transthoracic and the transesophageal approach. J Am Coll Cardiol 1989 14 631 8
283. Thuny F, Di Salvo G, Belliard O, Risk of embolism and death in infective endocarditis: prognostic value of echocardiography: a prospective multicenter study. Circulation 2005 112 69 75
284. Eishi K, Kawazoe K, Kuriyama Y, Kitoh Y, Kawashima Y, Omae T, Surgical management of infective endocarditis associated with cerebral complications. Multi-center retrospective study in Japan. J Thorac Cardiovasc Surg 1995 110 1745 55
285. Barsic B, Dickerman S, Krajinovic V, Influence of the timing of cardiac surgery on the outcome of patients with infective endocarditis and stroke. Clin Infect Dis 2013 56 209 17
286. García-Cabrera E, Fernández-Hidalgo N, Almirante B, Neurological complications of infective endocarditis: risk factors, outcome, and impact of cardiac surgery: a multicenter observational study. Circulation 2013 127 2272 84